MAP2K7 and cancer: In contrast to dominant mutations of EGFR, NF1, RAS, and RAF, there are some rare activating mutations of Sos, MEK, and ERK in cancer genomes that constitutively turn on RAS/RAF/MEK/ERK signaling.